Log in to save to my catalogue

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ebb6f0258ac5423e94ff695deaf0b039

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial.
The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or...

Alternative Titles

Full title

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ebb6f0258ac5423e94ff695deaf0b039

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ebb6f0258ac5423e94ff695deaf0b039

Other Identifiers

ISSN

1741-7015

E-ISSN

1741-7015

DOI

10.1186/s12916-019-1445-z

How to access this item